Aurobindo intros generic Atripla, gets FDA nod for Arava
Aurobindo is offering a new generic, and the company also has received approval from the Food and Drug Administration for another generic.
Aurobindo is launching eefavirenz/emtricitabine/tenofovir disoproxil fumarate tablets, in a dosage strength of 600mg/200mg/300mg.
The medication is the generic of Gilead’s Atripla.
It is indicated as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg.
Efavirenz/emtricitabine/tenofovir disoproxil fumarate tablets has a market value of roughly $482 million, for the 12 months ending January 2021, according to IQVIA.
Aurobindo received the FDA’s blessing for leflunomide tablets, in dosage strengths of 10 mg and 20 mg.
The product is the generic of Sanofi-Aventis’ Arava tablets.
It is indicated for the treatment of adults with active rheumatoid arthritis.
Leflunomide tablets have a market value of about $51.2 million for the 12 months ending February 2021, according to IQVIA.